home / stock / ucbjy / ucbjy quote
Last: | $63.676 |
---|---|
Change Percent: | -0.48% |
Open: | $64.38 |
Close: | $63.676 |
High: | $64.46 |
Low: | $63.6275 |
Volume: | 7,177 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$63.676 | $64.38 | $63.676 | $64.46 | $63.6275 | 7,177 | 04-18-2024 |
$64.07 | $62.95 | $64.07 | $64.175 | $62.91 | 71,706 | 04-17-2024 |
$63.31 | $63 | $63.31 | $63.5875 | $62.9 | 9,417 | 04-16-2024 |
$63 | $63.17 | $63 | $63.64 | $62.83 | 10,776 | 04-15-2024 |
$63.874 | $64.94 | $63.874 | $65 | $63.871 | 11,298 | 04-12-2024 |
$63.058 | $62.17 | $63.058 | $63.24 | $62.17 | 8,494 | 04-11-2024 |
$61.94 | $61.61 | $61.94 | $61.94 | $61.59 | 10,455 | 04-10-2024 |
$61.79 | $62.16 | $61.79 | $62.16 | $61.74 | 4,597 | 04-09-2024 |
$62.141 | $61.91 | $62.141 | $62.141 | $61.88 | 4,103 | 04-08-2024 |
$61.81 | $63 | $61.81 | $63 | $61.74 | 9,178 | 04-05-2024 |
$62.2532 | $63.14 | $62.2532 | $63.152 | $62.2532 | 9,858 | 04-04-2024 |
$62.16 | $61.6575 | $62.16 | $62.16 | $61.6575 | 56,601 | 04-03-2024 |
$61.6975 | $61.15 | $61.6975 | $61.85 | $61.1475 | 8,468 | 04-02-2024 |
$61.42 | $60.8575 | $61.42 | $61.42 | $60.756 | 3,273 | 04-01-2024 |
$61.615 | $61.262 | $61.615 | $61.74 | $61.262 | 4,504 | 03-29-2024 |
$61.615 | $61.262 | $61.615 | $61.74 | $61.262 | 4,504 | 03-28-2024 |
$61.57 | $61.57 | $61.57 | $61.74 | $61.1 | 6,213 | 03-27-2024 |
$61.87 | $61.628 | $61.87 | $61.975 | $61.6 | 5,190 | 03-26-2024 |
$62.45 | $62.454 | $62.45 | $62.53 | $62.39 | 4,632 | 03-25-2024 |
$61.77 | $61.18 | $61.77 | $61.77 | $61.18 | 6,483 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting PR Newswire Diverse and patient-focused data set comprises 17 abstracts including one oral presentation Features new data analyse...
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa PR Newswire Campaign offers resources and information about hidradenitis suppurativa (HS) and amplifies diverse patient voices and stories to reach p...
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations PR Newswire Application in moderate-to-severe hidradenitis suppurativa based on results from two...